Compare SHAK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | CELC |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2014 | 2017 |
| Metric | SHAK | CELC |
|---|---|---|
| Price | $88.85 | $114.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 8 |
| Target Price | ★ $115.65 | $107.88 |
| AVG Volume (30 Days) | ★ 1.1M | 646.9K |
| Earning Date | 04-30-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,445,306,000.00 | N/A |
| Revenue This Year | $16.38 | N/A |
| Revenue Next Year | $14.92 | $706.83 |
| P/E Ratio | $81.27 | ★ N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $72.93 | $7.58 |
| 52 Week High | $142.23 | $120.32 |
| Indicator | SHAK | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 55.02 |
| Support Level | $85.64 | $99.38 |
| Resistance Level | $89.42 | $117.27 |
| Average True Range (ATR) | 3.84 | 5.98 |
| MACD | -0.45 | 0.12 |
| Stochastic Oscillator | 58.04 | 76.41 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.